For patients with HER2+ metastatic breast cancer (MBC) previously treated with trastuzumab and a taxane and who have received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy KADCYLA EXTENDED MEDIAN OVERALL SURVIVAL BY NEARLY 6 MONTHS
30.9 months vs 25.1 months with lapatinib + capecitabine Overall survival was a co-primary endpoint. (HR=0.682; 95% CI: 0.548, 0.849; P=0.0006)
What is KADCYLA?
Find out the proposed mechanism of action of KADCYLA and how it is
thought to work.
KADCYLA Access Solutions
Genentech offers options to help eligible patients with the
out-of-pocket (OOP) costs of their Genentech medicines.
Get updates from Genentech
Receive information about KADCYLA and other Genentech products.